4th Quarter - Report

CAPITOL COUNSEL LLC for ASTRAZENECA PHARMACEUTICALS, LP

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health care reform; Federal Food, Drug and Cosmetic Act Issues, including drug safety and comparative effectiveness, follow-on biologics and related provisions in HR 1956, Patient Protection and Innovative Biologic Medicines Act, HR 5629, Pathway for Biosimilars Act, and S. 1695, Biologics Price Competition and Innovation Act.

LobbyistCovered position, as disclosed
SHANNON FINLEY —
SARA FRANKO —
JAMES GOULD —
DENISE HENRY MORRISEY —
DAVID JONES —
JOHN D RAFFAELLI —
RICHARD LYLES SULLIVAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5629 (110th), H.R. 1956 (110th), S. 1695 (110th)

Medicare/Medicaid MMM

Medicare Medicaid coverage, coding and reimbursement of pharmaceuticals, including policies for budesonide inhalation therapies; Medicaid prescription drug rebate and possible related provisions in S. 3101 and HR 6133, Medicare Improvements for Patients and Providers Act.

LobbyistCovered position, as disclosed
SHANNON FINLEY —
SARA FRANKO —
JAMES GOULD —
DENISE HENRY MORRISEY —
DAVID JONES —
JOHN D RAFFAELLI —
RICHARD LYLES SULLIVAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3101 (110th), H.R. 6133 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.